Systolic Pressure, Diastolic Pressure, or Pulse Pressure as a Cardiovascular Risk Factor in Renal Disease
- 192 Downloads
Chronic kidney disease is a leading global health problem with an increasing prevalence. Hypertension is present in most patients with chronic kidney disease, and hypertension-related nephrosclerosis is a top cause of progressive renal damage and end-stage renal disease. Systolic blood pressure (BP) and pulse pressure, together with nocturnal BP, are the most important factors favoring the progression of renal failure. Consequently, strict control of BP and other cardiovascular risk factors is required, including an adequate degree of suppression of the renin-angiotensin system in every patient.
KeywordsSystolic blood pressure Diastolic blood pressure Blood pressure Hypertension Chronic kidney disease End-stage renal disease Renal failure Renin-angiotensin system
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 18.Franklin SS: Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J Hypertens 1999, 17:S29–S36.Google Scholar
- 27.• Lawes CMM, Van der Horn S, Rodgers A: Global burden of blood pressure related disease, 2001. Lancet 2008, 371:1513–1518. This study assesses the extent and global distribution of the burden of BP-related disease. It concludes that low-income and middle-income countries and middle-aged, prehypertensive people cause most of the disease burden.CrossRefPubMedGoogle Scholar
- 33.•• Mancia G, Laurent S, Agabiti-Rosei E, et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009, 18:308–347. This is an important review of current guideline recommendations according to results of the latest trials.CrossRefPubMedGoogle Scholar
- 34.•• Zanchetti A, Grassi G, Mancia G: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009, 27:923–934. This paper is a critical discussion of the most debated items included in the most recent international guidelines.CrossRefPubMedGoogle Scholar
- 45.• Redon J, Plancha E, Swift P, et al.: Nocturnal blood pressure and progression to end-stage renal disease or death in nondiabetic chronic kidney disease stages 3 and 4. J Hypertens 2010, 28:602–607. This interesting study assesses the role of office and ambulatory blood pressure measurements on the development of ESRD in nondiabetic CKD.CrossRefPubMedGoogle Scholar
- 55.Segura J, Campo C, Ruilope LM: Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004, 6(suppl 92):S1–S5.Google Scholar
- 62.Solomon SD, Rice MM, Jablonski K, et al.; Prevention of Events with ACE inhibition (PEACE) Investigators: Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006, 114:26–31.CrossRefPubMedGoogle Scholar
- 63.Bakris GL, Sarafidis PA, Weir MR, et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173–1181.CrossRefPubMedGoogle Scholar